TRUP as A Drug Target: Potential Therapeutic Uses (G6130)

Target Name: RPL7A

NCBI ID: G6130

RPL7A

TRUP as A Drug Target: Potential Therapeutic Uses

RPL7A (Tripteridine-Sulfate Pyruvate Lactate), also known as TRUP, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the citric acid cycle, a process that is essential for the production of energy in the form of ATP. The citric acid cycle is also known as the Krebs cycle or TCA cycle, and it is a central component of cellular metabolism.

TRUP has been shown to play a crucial role in the regulation of cellular energy metabolism. It is a key player in the transition from the G1 to the G2 phase of cell division, a critical step in the regulation of cell growth and proliferation. In addition , TRUP has been shown to play a role in the regulation of cell death, both in the context of programmed cell death (apoptosis) and in the context of uncontrolled cell growth.

As a drug target, TRUP is of great interest to researchers because of its potential to intervene in a wide range of cellular processes. One of the main goals of drug development is to identify compounds that can modulate the activity of TRUP and improve its function as a drug target.

TRUP as a drug target

TRUP has been shown to be a potential drug target in a number of different contexts.

First, TRUP has been shown to be a potential drug target for the treatment of cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. The citric acid cycle is a key player in the regulation of cellular growth and proliferation , and TRUP has been shown to play a critical role in this process. By modulating the activity of TRUP, researchers may be able to inhibit the growth and proliferation of cancer cells.

Second, TRUP has been shown to be a potential drug target for the treatment of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of debilitating symptoms. The citric acid cycle is also involved in the production of the neurotransmitter acetylcholine, which is essential for the function of the nervous system. TRUP has been shown to play a critical role in the regulation of the citric acid cycle, and may be a useful target for the treatment of neurodegenerative diseases.

Third, TRUP has been shown to be a potential drug target for the treatment of cardiovascular disease. Cardiovascular disease is a leading cause of death in adults around the world. The citric acid cycle is involved in the production of the molecule NADH, which is essential for the production of ATP in the cell. TRUP has been shown to play a critical role in the regulation of the citric acid cycle, and may be a useful target for the treatment of cardiovascular disease.

Drugs that target TRUP

Several drugs that have been shown to target TRUP have been developed and are in use. These drugs work by inhibiting the activity of TRUP or by modulating its function in some other way.

One of the most well-known drugs that targets TRUP is used to treat hypertension, a condition characterized by high blood pressure. This drug, called ACE inhibitors, work by inhibiting the activity of the enzyme ACE, which is responsible for breaking down a hormone called angiotensin II. By inhibiting ACE activity, ACE inhibitors can lower blood pressure and improve blood flow to the body.

Another drug that targets TRUP is used to treat

Protein Name: Ribosomal Protein L7a

Functions: Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547)

The "RPL7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets